Theralase makes positive progress on Phase II study on bladder cancer; targets breakthrough designation with FDA

–News Direct– Theralase Technologies Inc. CEO Roger DuMoulin-White, joined Proactive's Stephen Gunnion to discuss the company's third-quarter 2023 operational highlights. The company successfully raised $1.17…

View More Theralase makes positive progress on Phase II study on bladder cancer; targets breakthrough designation with FDA